Autologous Anti-CD5 CAR T-lymphocytes MB-105
autologous anti-cd5 car t-lymphocytes mb-105
A preparation of genetically modified autologous T-cells expressing a chimeric antigen receptor (CAR) directed against cluster of differentiation 5 (CD5), with potential immunomodulating and antineoplastic activities. Upon administration, the autologous anti-CD5 CAR T-lymphocytes MB-105 target and bind to CD5-expressing tumor cells, thereby inducing selective cytotoxicity in CD5-expressing tumor cells. CD5 is a T-cell surface glycoprotein expressed on the surface of normal T-cells and overexpressed on various B- and T-cell malignancies.